Payment overview · 2025
General Payments
$1,769.36
105 reported records · 16 companies
Healthcare provider profile · identity verified
James Noah Eickholz, MD
Allopathic & Osteopathic Physicians|Family Medicine · PADUCAH, KY · NPI 1831120930
Verified facts
What the public records show
CMS Open Payments records show James Noah Eickholz, MD received $1,769.36 in general payments during 2025 across 105 reported records.
Novo Nordisk Inc accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $497.23 | 28.1% | 30 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $254.41 | 14.4% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $229.46 | 13.0% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $202.36 | 11.4% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $122.73 | 6.9% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $109.04 | 6.2% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $68.20 | 3.9% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $59.51 | 3.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.37 | 2.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.04 | 2.0% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $33.87 | 1.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.63 | 1.9% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $30.40 | 1.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.28 | 1.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.22 | 1.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.61 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,769.36 | 105 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $219.49 | 17 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $202.36 | 13 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $195.36 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $186.63 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $186.03 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $154.75 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $154.11 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $154.11 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $143.20 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $122.73 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $122.73 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $109.04 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $88.88 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $68.20 | 4 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $55.81 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $45.99 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.37 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $40.37 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.37 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $35.04 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.92 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $33.87 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.63 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $30.40 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 122 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 90 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 93 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
114 | 37 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
90 | 22 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
93 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 571 | 147 |
| Atorvastatin Calcium | Atorvastatin Calcium | 538 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 528 | 166 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 518 | 174 |
| Losartan Potassium | Losartan Potassium | 426 | 130 |
| Pravastatin Sodium | Pravastatin Sodium | 350 | 105 |
| Metformin Hcl | Metformin Hcl | 348 | 104 |
| Pantoprazole Sodium | Pantoprazole Sodium | 348 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 341 | 101 |
| Lisinopril | Lisinopril | 338 | 107 |
| Omeprazole | Omeprazole | 330 | 99 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 277 | 97 |
| Simvastatin | Simvastatin | 268 | 82 |
| Furosemide | Furosemide | 253 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 240 | 78 |
| Gabapentin | Gabapentin | 235 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 224 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 217 | 65 |
| Famotidine | Famotidine | 216 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 199 | 59 |
| Carvedilol | Carvedilol | 198 | 62 |
| Trazodone Hcl | Trazodone Hcl | 197 | 67 |
| Benazepril Hcl | Benazepril Hcl | 195 | 58 |
| Montelukast Sodium | Montelukast Sodium | 193 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 185 | 54 |
| Methylprednisolone | Methylprednisolone | 183 | 165 |
| Celecoxib | Celecoxib | 180 | 58 |
| Allopurinol | Allopurinol | 175 | 54 |
| Quetiapine Fumarate | Quetiapine Fumarate | 173 | 38 |
| Tramadol Hcl | Tramadol Hcl | 166 | 49 |
| Azithromycin | Azithromycin | 162 | 146 |
| Potassium Chloride | Potassium Chloride | 153 | 48 |
| Meloxicam | Meloxicam | 152 | 56 |
| Bupropion Xl | Bupropion Hcl | 150 | 47 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 149 | 59 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 145 | 40 |
| Spironolactone | Spironolactone | 141 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 134 | 48 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 132 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 129 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 124 | 36 |
| Buspirone Hcl | Buspirone Hcl | 123 | 43 |
| Eliquis | Apixaban | 122 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 120 | 57 |
| Metformin Hcl Er | Metformin Hcl | 119 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 119 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 118 | 41 |
| Finasteride | Finasteride | 117 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 33 |
| Glimepiride | Glimepiride | 114 | 29 |
| Synthroid | Levothyroxine Sodium | 114 | 37 |
| Ozempic | Semaglutide | 112 | 27 |
| Prednisone | Prednisone | 111 | 70 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 101 | 35 |
| Jardiance | Empagliflozin | 100 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 30 |
| Memantine Hcl | Memantine Hcl | 99 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 95 | 81 |
| Mounjaro | Tirzepatide | 93 | 20 |
| Farxiga | Dapagliflozin Propanediol | 90 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 88 | 26 |
| Mupirocin | Mupirocin | 82 | 62 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 81 | 19 |
| Ezetimibe | Ezetimibe | 80 | 25 |
| Nebivolol Hcl | Nebivolol Hcl | 78 | 18 |
| Azelastine Hcl | Azelastine Hcl | 77 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 18 |
| Xarelto | Rivaroxaban | 77 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 24 |
| Irbesartan | Irbesartan | 75 | 23 |
| Mirtazapine | Mirtazapine | 75 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 27 |
| Bumetanide | Bumetanide | 72 | 28 |
| Doxepin Hcl | Doxepin Hcl | 71 | 23 |
| Fenofibrate | Fenofibrate | 71 | 22 |
| Pregabalin | Pregabalin | 71 | 29 |
| Repatha Sureclick | Evolocumab | 69 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 20 |
| Sertraline Hcl | Sertraline Hcl | 64 | 21 |
| Lorazepam | Lorazepam | 61 | 19 |
| Alprazolam | Alprazolam | 58 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 49 |
| Fluconazole | Fluconazole | 56 | 40 |
| Januvia | Sitagliptin Phosphate | 56 | 11 |
| Levofloxacin | Levofloxacin | 56 | 46 |
| Sucralfate | Sucralfate | 56 | 22 |
| Ramipril | Ramipril | 55 | 13 |
| Lovastatin | Lovastatin | 53 | 14 |
| Alendronate Sodium | Alendronate Sodium | 52 | 17 |
| Cefdinir | Cefdinir | 52 | 42 |
| Indapamide | Indapamide | 52 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 50 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 12 |
| Myrbetriq | Mirabegron | 50 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 15 |
| Valacyclovir | Valacyclovir Hcl | 49 | 24 |
| Verapamil Er | Verapamil Hcl | 47 | 11 |
| Clonidine Hcl | Clonidine Hcl | 45 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Rybelsus | Semaglutide | 41 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 21 |
| Meclizine Hcl | Meclizine Hcl | 38 | 22 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | 13 |
| Topiramate | Topiramate | 37 | 12 |
| Lansoprazole | Lansoprazole | 36 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | 15 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | 11 |
| Naproxen | Naproxen | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | 11 |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | 11 |
| Amoxicillin | Amoxicillin | 25 | 22 |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Cephalexin | Cephalexin | 21 | 16 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Nystatin | Nystatin | 19 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 17 | suppressed |
| Mirabegron Er | Mirabegron | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 14 |
| Glipizide | Glipizide | 15 | suppressed |
| Oxazepam | Oxazepam | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,769.36 · 105 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, Symbravo, TRINTELLIX, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error